Company: LIMN
Filing Date: 2025-07-03
Form Type: 8-K
Source: 0001104659-25-065663
Chunk: 1

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-03
Form: 8-K
Item: Item 8.01
Chunk 1
---
 Pharma’s
regulatory and commercial infrastructure, the consortium is poised to deliver meaningful innovation in one of oncology’s most challenging
frontiers.

Forward-Looking Statements

Certain statements in this report constitute forward-looking
statements. All statements, other than statements of present or historical fact, that address activities, events or developments that
Liminatus Pharma, Inc. expects, believes or anticipates will or may occur in the future, including statements about results of operations
and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and
expected future growth and profitability, are forward-looking statements. The words “will,” “may,” “believes,”
“anticipates,” “thinks,” “expects,” “estimates,” “plans,” “intends”
and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements
which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion
of strategy, plans or intentions, statements about management’s assumptions, projections or predictions of future events or market
outlook and any other statement, other than a statement of present or historical fact, are forward-looking statements.

Item 9.01 Financial Statements and Exhibits.